Daniel Connochie1, Ryan C Tingler2, José A Bauermeister2. 1. Department of Family and Community Health, School of Nursing, 418 Curie Blvd., Rm 235L, University of Pennsylvania, Philadelphia, PA 19104, United States. Electronic address: dconno@upenn.edu. 2. Department of Family and Community Health, School of Nursing, 418 Curie Blvd., Rm 235L, University of Pennsylvania, Philadelphia, PA 19104, United States.
Abstract
BACKGROUND: New cases of human immunodeficiency virus (HIV) among young men who have sex with men (YMSM) underscore the need to examine their willingness to use biomedical prevention methods, including an acceptable and efficacious HIV vaccine. We examined whether YMSM's vaccine altruism and vaccine-related socials concerns factors were associated with HIV vaccine acceptability across two vaccine efficacy scenarios, and their awareness and willingness to participate in HIV vaccine research. METHODS: This secondary analysis uses data from a mHealth trial with YMSM at heightened HIV risk (N = 137; 50% racial/ethnic minority; M = 21.7 years). Most YMSM (91.2%) had tested for HIV, and 17.5% (N = 24) reported a prior STI.We used paired-samples t-test to compare differences in efficacy acceptability (50% vs 85%), followed by multivariable regressions examining whether vaccine attitudes (altruism and social concerns) were associated with vaccine acceptability and awareness and willingness to participate in HIV vaccine trials. We controlled for age, education, race/ethnicity, prior HIV testing, and STI diagnosis in our analyses. RESULTS: Acceptability for the HIV vaccine with 85% efficacy (M = 8.86; SD = 1.76) was greater than acceptability in the 50% efficacy scenario (M = 7.60; SD = 2.58). Altruistic attitudes were associated with greater vaccine acceptability at 50% (β = 0.62) and 85% (β = 0.59) efficacy. Higher educational attainment was negatively associated with a vaccine with 50% efficacy (β = -0.20, but not for 85% efficacy. Greater vaccine-related social concerns were negatively associated with HIV vaccine research awareness (AOR = 0.38 (95% CI: 0.22, 0.67). Willingness to participate in a HIV vaccine trial was positively associated with age (β = 0.18) and altruism (β = 0.60), and negatively associated with education (β = -0.21). CONCLUSIONS: YMSM find HIV vaccines as an acceptable prevention modality and are willing to participate in HIV vaccine trials. Findings highlight the need to consider YMSM's altruistic and social concerns attitudes in HIV vaccine research and explore how to leverage these attitudes in research campaigns. ClinicalTrials.gov Identifier: NCT02842060.
BACKGROUND: New cases of human immunodeficiency virus (HIV) among young men who have sex with men (YMSM) underscore the need to examine their willingness to use biomedical prevention methods, including an acceptable and efficacious HIV vaccine. We examined whether YMSM's vaccine altruism and vaccine-related socials concerns factors were associated with HIV vaccine acceptability across two vaccine efficacy scenarios, and their awareness and willingness to participate in HIV vaccine research. METHODS: This secondary analysis uses data from a mHealth trial with YMSM at heightened HIV risk (N = 137; 50% racial/ethnic minority; M = 21.7 years). Most YMSM (91.2%) had tested for HIV, and 17.5% (N = 24) reported a prior STI.We used paired-samples t-test to compare differences in efficacy acceptability (50% vs 85%), followed by multivariable regressions examining whether vaccine attitudes (altruism and social concerns) were associated with vaccine acceptability and awareness and willingness to participate in HIV vaccine trials. We controlled for age, education, race/ethnicity, prior HIV testing, and STI diagnosis in our analyses. RESULTS: Acceptability for the HIV vaccine with 85% efficacy (M = 8.86; SD = 1.76) was greater than acceptability in the 50% efficacy scenario (M = 7.60; SD = 2.58). Altruistic attitudes were associated with greater vaccine acceptability at 50% (β = 0.62) and 85% (β = 0.59) efficacy. Higher educational attainment was negatively associated with a vaccine with 50% efficacy (β = -0.20, but not for 85% efficacy. Greater vaccine-related social concerns were negatively associated with HIV vaccine research awareness (AOR = 0.38 (95% CI: 0.22, 0.67). Willingness to participate in a HIV vaccine trial was positively associated with age (β = 0.18) and altruism (β = 0.60), and negatively associated with education (β = -0.21). CONCLUSIONS: YMSM find HIV vaccines as an acceptable prevention modality and are willing to participate in HIV vaccine trials. Findings highlight the need to consider YMSM's altruistic and social concerns attitudes in HIV vaccine research and explore how to leverage these attitudes in research campaigns. ClinicalTrials.gov Identifier: NCT02842060.
Authors: Michael P Arnold; Michele Andrasik; Stewart Landers; Shelly Karuna; Matthew J Mimiaga; Steven Wakefield; Kenneth Mayer; Susan Buchbinder; Beryl A Koblin Journal: Am J Public Health Date: 2014-06-12 Impact factor: 9.308
Authors: Peter A Newman; Naihua Duan; Sung-Jae Lee; Ellen T Rudy; Danielle S Seiden; Lisa Kakinami; William E Cunningham Journal: Vaccine Date: 2005-11-21 Impact factor: 3.641
Authors: Mary A Allen; Thomas S Liang; Thomas La Salvia; Brian Tjugum; Robert J Gulakowski; Matthew Murguía Journal: J Acquir Immune Defic Syndr Date: 2005-12-15 Impact factor: 3.731
Authors: Jose R Castillo-Mancilla; Susan E Cohn; Supriya Krishnan; Michelle Cespedes; Michelle Floris-Moore; Gail Schulte; Gregory Pavlov; Donna Mildvan; Kimberly Y Smith Journal: HIV Clin Trials Date: 2014 Jan-Feb
Authors: Ardvin Kester S Ong; Yogi Tri Prasetyo; Fae Coleen Lagura; Rochelle Nicole Ramos; Jose Ma Luis Salazar; Keenan Mark Sigua; Jomy Anne Villas; Thanatorn Chuenyindee; Reny Nadlifatin; Satria Fadil Persada; Kriengkrai Thana Journal: Public Health Pract (Oxf) Date: 2022-07-19
Authors: Leonn Mendes Soares Pereira; Eliane Dos Santos França; Iran Barros Costa; Igor Tenório Lima; Amaury Bentes Cunha Freire; Francisco Lúzio de Paula Ramos; Talita Antonia Furtado Monteiro; Olinda Macedo; Rita Catarina Medeiros Sousa; Felipe Bonfim Freitas; Igor Brasil Costa; Antonio Carlos Rosário Vallinoto Journal: Sci Rep Date: 2021-09-16 Impact factor: 4.996
Authors: Audrey Harkness; Brooke G Rogers; Raymond Balise; Daniel Mayo; Elliott R Weinstein; Steven A Safren; John E Pachankis Journal: AIDS Behav Date: 2021-01-23
Authors: Daniel Teixeira da Silva; Katie Biello; Willey Y Lin; Pablo K Valente; Kenneth H Mayer; Lisa Hightow-Weidman; José A Bauermeister Journal: Vaccines (Basel) Date: 2021-03-01